Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. Design studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID 19 hospitalized meta-analysis

DisCoVeRy (remdesivir)
 
NCT04315948
RCTremdesivirstandard of careCOVID 19 hospitalizedsome concern
429/428 no results
    Mahajan RCTremdesivirstandard of careCOVID 19 hospitalizedsome concern
    41/41 inconclusive
      NIH NIAID ACTT-1
       
      NCT04280705
      RCTremdesivirplaceboCOVID 19 hospitalizedsome concern
      541/521 suggested
      • suggested 45 % decrease in deaths,deaths (time to event analysis only) with a moderate degree of certainty due to some concern in risk of bias
      • suggested 29 % increase in clinical improvement,clinical improvement (time to event analysis only) (PE) with a moderate degree of certainty due to some concern in risk of bias
      • suggested 35 % increase in clinical improvement (28-day) with a moderate degree of certainty due to some concern in risk of bias
      SOLIDARITY (remdesivir)
       
      NCT04315948
      RCTremdesivirstandard of careCOVID 19 hospitalizedsome concern
      2750/2725 inconclusive
      • inconclusive 5 % decrease in deaths,deaths (time to event analysis only) (PE) with a moderate degree of certainty due to some concern in risk of bias

      COVID 19 all comers meta-analysis

      Andreas (NOR-Solidarity)
       
      NCT04321616
      RCTremdesivirCOVID 19 all comerslow
      43/58 ongoing
        Norwegian NOR study (remdesivir)
         
        NCT04321616
        RCTremdesivirstandard of careCOVID 19 all comerssome concern
        43/58 no results

          COVID-19 mild to moderate meta-analysis

          GS-US-540-5773 (Goldman)
           
          NCT04292899
          RCTremdesivirremdesivirCOVID-19 mild to moderatesome concern
          200/197 suggested
          • suggested 53 % increase in clinical improvement (14-day) with a moderate degree of certainty due to some concern in risk of bias
          GS-US-540-5774, 10 days
           
          NCT04292730
          RCTremdesivirstandard of careCOVID-19 mild to moderatesome concern
          197/200 safety concern
          • suggested 58 % increase in clinical improvement (14-day) with a moderate degree of certainty due to some concern in risk of bias
          • suggested 88 % increase in clinical improvement (28-day) with a moderate degree of certainty due to some concern in risk of bias
          • statistically significant 63 % increase in adverse events with a moderate degree of certainty due to some concern in risk of bias
          The primary endpoint was not met, no odds ratio is reported because the proportional odds assumption was not met
          GS-US-540-5774, 5 days
           
          NCT04292730
          RCTremdesivirstandard of careCOVID-19 mild to moderatesome concern
          199/200 conclusif
          • demonstrated 65 % increase in clinical improvement (PE) with a moderate degree of certainty due to some concern in risk of bias

          COVID-19 severe or critically meta-analysis

          CAP-China (Wang et al.)
           
          NCT04257656
          RCTremdesivirplaceboCOVID-19 severe or criticallylow
          158/79 inconclusive
          • inconclusive 23 % increase in clinical improvement,clinical improvement (time to event analysis only) (PE) with a high degree of certainty due to low risk of bias

          PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
          Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).